TWD 67.3
(3.7%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 160.83 Million TWD | 168.05% |
2022 | 60 Million TWD | -25.0% |
2021 | 80 Million TWD | -38.46% |
2020 | 130 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 149.02 Million TWD | -7.34% |
2024 Q2 | 149.78 Million TWD | 0.51% |
2023 Q2 | 436.46 Million TWD | 627.44% |
2023 FY | 160.83 Million TWD | 168.05% |
2023 Q1 | 60 Million TWD | 0.0% |
2023 Q4 | 160.83 Million TWD | -27.69% |
2023 Q3 | 222.42 Million TWD | -49.04% |
2022 Q4 | - TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Allied Biotech Corporation | 796.6 Million TWD | 79.81% |
GeneFerm Biotechnology Co., Ltd. | 152.07 Million TWD | -5.755% |
Easywell Biomedicals, Inc. | 386.34 Million TWD | 58.371% |
TTY Biopharm Company Limited | 1.91 Billion TWD | 91.602% |
Synmosa Biopharma Corporation | 2.43 Billion TWD | 93.408% |
Orient EuroPharma Co., Ltd. | 4.84 Billion TWD | 96.679% |
Center Laboratories, Inc. | 5.62 Billion TWD | 97.14% |
Tien Liang BioTech Co., Ltd. | 84.65 Million TWD | -89.975% |
Orient Pharma Co., Ltd. | 716.92 Million TWD | 77.567% |
InnoPharmax Inc. | 21.49 Million TWD | -648.086% |
Excelsior Biopharma Inc. | 377.4 Million TWD | 57.385% |
DV Biomed Co., Ltd. | 387.69 Million TWD | 58.516% |
Foresee Pharmaceuticals Co., Ltd. | 228.25 Million TWD | 29.54% |
Handa Pharmaceuticals, Inc. | 13.24 Million TWD | -1114.736% |
UniPharma Co., Ltd. | 277 Thousand TWD | -57961.733% |
Anxo Pharmaceutical Co., Ltd. | 787.84 Million TWD | 79.586% |
Alar Pharmaceuticals Inc. | 1.4 Million TWD | -11314.549% |
Winston Medical Supply Co., Ltd. | 107.32 Million TWD | -49.849% |
Mercury Biopharmaceutical Corporation | 42.34 Million TWD | -279.775% |
Bioray Biotech Co., Ltd | 69.79 Million TWD | -130.443% |
TSH Biopharm Corporation Limited | 7.84 Million TWD | -1950.631% |